Celon Pharma S.A. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was PLN 41.1 million compared to PLN 38.09 million a year ago. Net loss was PLN 7.83 million compared to net income of PLN 1.81 million a year ago. Basic loss per share from continuing operations was PLN 0.17 compared to basic earnings per share from continuing operations of PLN 0.04 a year ago. Diluted loss per share from continuing operations was PLN 0.17 compared to diluted earnings per share from continuing operations of PLN 0.04 a year ago. For the nine months, revenue was PLN 146.19 million compared to PLN 115.18 million a year ago. Net loss was PLN 7.53 million compared to net income of PLN 2.79 million a year ago. Basic loss per share from continuing operations was PLN 0.15 compared to basic earnings per share from continuing operations of PLN 0.06 a year ago. Diluted loss per share from continuing operations was PLN 0.15 compared to diluted earnings per share from continuing operations of PLN 0.06 a year ago.